Research Reports

Key takeaways

Operating income was -$4.1M, an 18.0% improvement from -$5.0M in Q1 FY2025 as losses narrowed.

Net income was -$3.8M, 14.5% better than -$4.5M prior year due to lower operating expenses.

Diluted EPS was -$5.89 versus -$0.22 in Q1 FY2025, reflecting increased per-share loss impact.

Net cash used in operating activities was $3.2M, down from $4.0M prior year primarily from lower R&D expenses.

Full analysis

For the three months ended March 31, 2026, enVVeno Medical Corporation reported an operating loss of $4.1 million, representing an 18.0% narrowing from $5.0 million in the prior year period. This improvement reflects disciplined cost management during the transition from the VenoValve pivotal study to development of the enVVe System. As follow-up activities for VenoValve participants decrease over time, related costs declined, enabling focus on the next-generation transcatheter platform. Net income followed a similar trajectory at -$3.8 million, a 14.5% enhancement from -$4.5 million, driven by the net effect of lower operating expenses.

NVNO · enVVeno Medical Corporation

Summary

Key takeaways

Full analysis